The levels of Ki-67 expression in the CX3CR1+ CD8+ T cells were significantly higher than in the CX3CR1−(CD27lo CX3CR1− and CD27hi CX3CR1−) subsets 2 weeks after anti-CTLA-4/PD-L1 therapy in CT26 tumor-bearing mice (Fig. 3a). This evidence concerns the gene CX3CR1 and neoplasm.